Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346086 · ClinicalTrials.gov registry record · Phase 2
DNA Vaccine for Ragweed Allergic Adults
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00346086: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00346086 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00346086, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Various chemical modifications of allergens have been attempted to enhance efficacy, improve safety, and foster compliance with IT. These approaches have been unsuccessful - in that the allergenicity and immunogenicity have either decreased, or increased in tandem, with no resultant efficacy: safety benefit ratio. This study utilizes an adjuvant approach in which synthetic immunostimulatory DNA is conjugated to ragweed allergen in an attempt to modulate both the clinical and immunologic allergic response to ragweed exposure in ragweed-allergic patients with seasonal rhinitis.
Interventions
- DRUG AIC (Amb a 1 Immunostimulatory Conjugate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2001-05-18 |
| Est. Completion | 2001-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346086
The ClinicalTrials.gov registry entry for NCT00346086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AIC (Amb a 1 Immunostimulatory Conjugate) is the first listed.
NCT00346086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346086 about?
NCT00346086 is a clinical study titled "DNA Vaccine for Ragweed Allergic Adults". Various chemical modifications of allergens have been attempted to enhance efficacy, improve safety, and foster compliance with IT. These approaches have been unsuccessful - in that the allergenicity and immunogenicity have either decreased, or increased in tandem, with no resultant efficacy: safety...
What is the current status of trial NCT00346086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2001-05-18. Estimated completion is 2001-08-21.
What interventions are being tested in trial NCT00346086?
The interventions under investigation include: AIC (Amb a 1 Immunostimulatory Conjugate) (DRUG).
Who is sponsoring clinical trial NCT00346086?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.